Transducin-Like Enhancer of Split 3 (TLE3) expression is associated with taxane sensitivity in non-serous ovarian carcinoma in a three-cohort study

BACKGROUND: Chemo-resistance is a major challenge in ovarian cancer treatment, resulting in poor survival rates. Identifying markers of treatment response is imperative for improving outcome while minimizing unnecessary side effects. We have previously demonstrated that expression of transducin-like...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Epidemiol Biomarkers Prev
Glavni autori: Ring, Brian Z., Murali, Rajmohan, Soslow, Robert A., Bowtell, David D.L., Fereday, Sian, deFazio, Anna, Traficante, Nadia, Kennedy, Catherine J, Brand, Alison, Sharma, Raghwa, Harnett, Paul, Samimi, Goli
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984690/
https://ncbi.nlm.nih.gov/pubmed/29531130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-17-1101
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items